Cost-effectiveness analysis of sequential paclitaxel adjuvant chemotherapy for patients with node positive primary breast cancer

Journal of the Medical Association of Thailand

Volumn 89, Issue 5, 2006, Pages 690-698

  Limwattananon, Supon ^a   Limwattananon, Chulaporn ^a   Maoleekulpairoj, Savitree ^b   Soparatanapaisal, Noppadol ^c  

^a KHON KAEN UNIVERSITY   (Thailand)

^b Health Systems Research Institute   (Thailand)

^c MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Adjuvant chemotherapy; Cost effectiveness; Early stage breast cancer; Markov model; Paclitaxel; Taxanes

Indexed keywords

CAPECITABINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; GEMCITABINE; NAVELBINE; PACLITAXEL;

ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE FREE SURVIVAL; DRUG COST; DRUG EFFICACY; FEMALE; FOLLOW UP; HEALTH CARE COST; HUMAN; LIFE EXPECTANCY; LYMPH NODE METASTASIS; MONOTHERAPY; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; TERMINAL CARE; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COST-BENEFIT ANALYSIS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; LYMPH NODES; MARKOV CHAINS; PACLITAXEL; SURVIVAL ANALYSIS;

EID: 33646759975     PISSN: 01252208     EISSN: 01252208     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Martin N, Cheirsilpa A. Breast. In: Sriplung H, Sontipong S, Martin N, editors. Cancer in Thailand. Vol. III (1995-1997). Bangkok: Bangkok Medical Publisher; 2003: 47-8.
2. Sriplung H. Projection of cancer problems. In: Sriplung H, Sontipong S, Martin N, editors. Cancer in Thailand. Vol. III (1995-1997). Bangkok: Bangkok Medical Publisher; 2003: 82-4.
3. Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 1995; 332: 901-6.
4. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomized trials. Lancet 1998; 352: 930-42.
5. Cheirsilpa A, Chaiverawattana A, Jariyaradsak S, editors. Clinical practice guideline for breast cancer: investigation and management 2003-2004. National Cancer Prevention and Control Program Board, National Cancer Institute of Thailand. Bangkok: Agricultural Cooperative Federation of Thailand Publisher; 2003: 54-79.
6. Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003; 21: 976-83.
7. Mamounous EP, Bryant J, Lembersky BC, Fehrenbacher L, Sedlacek SM, Fisher B, et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 2005; 23: 3686-96.
8. Nabholtz JM, Pienkowski T, Mackey J, Pawlick M, Guastalla JP, Vogel C, et al. Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer patients: interim analysis of the BCIRG 001 study [abstract]. Proc Am Soc Clin Oncol 2002; 21: 141.
9. Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, et al. TAC improves disease free survival and overall survival over FAC in node positive early breast cancer patients, BCIRG 001: 55 months follow-up Breast Cancer Research and Treatment, 82: Special Issue: 26th Annual San Antonio Breast Cancer Symposium. 2003; abstract 43.
10. National Drug Committee. National List of Essential Medicines. Nonthaburi: Ministry of Public Health; 2004.
11. Beck JR, Pauker SG. The Markov process in medical prognosis. Med Decis Making 1983; 3: 419-58.
12. Naimark D, Krahn MD, Naglie G, Redelmeier DA, Detsky AS. Primer on medical decision analysis: part 5-working on the Markov process. Med Decis Making 1997; 17: 152-9
13. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993; 13: 322-38.
14. Gold MR, Siegel JE, Russell LB, Weinstein MC, editors. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.
15. DATA 3.5, Williamstown, MA: TreeAge Software Inc; 2001.
16. Lee JH, Glick HA, Hayman JA, Solin LJ. Decision-analytic model and cost-effectiveness evaluation of postmastectomy radiation therapy in high-risk premenopausal breast cancer patients. J Clin Oncol 2002; 20: 2713-25.
17. Smith TJ, Davidson NE, Schapira DV, Grunfeld E, Muss HB, Vogel VG III, et al. American Society of Clinical Oncology 1998 update of recommended breast cancer surveillance guidelines. J Clin Oncol 1999; 17: 1080-2.
18. Messori A, Becagli P, Trippoli S, Tendi E. Cost-effectiveness of adjuvant chemotherapy with cyclophosphamide + methotrexate + fluorouracil in patients with node-positive breast cancer. Eur J Clin Pharmacol 1996; 51:111-6.
19. Norum J. Adjuvant cyclophosphamide, methotrexate, fluorouracil (CMF) in breast cancer - is it cost-effective? Acta Oncol 2000; 39: 33-9.
20. Teerawattananon Y. Cost-effectiveness of renal replacement therapy in Thailand. In: Tangcharoensathien V, Kasemsap V, Supaporn T, Teerawattananon Y, editors. Universal access to renal replacement therapy in Thailand: a policy analysis. Nonthaburi: Health Systems Research Institute and National Health Security Office; 2005.
21. Commission on macroeconomics and health. Investing in health for economic development. Geneva: World Health Organization; 2001.
22. World Bank. World development indicators 2005. Washington, DC: World Bank; 2005.